Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/S2213-2600(14)70100-6 http://scihub22266oqcxt.onion/10.1016/S2213-2600(14)70100-6 C4154311!4154311!24836205     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Lancet+Respir+Med 2014 ; 2 (7): 539-47 Nephropedia Template TP {{tp|p=24836205|t=2014. A randomized placebo-controlled trial of ataluren for the treatment of nonsense mutation cystic fibrosis |pdf=|usr=}}{{24836205}} gab.com Text A randomized placebo-controlled trial of ataluren for the treatment of nonsense mutation cystic fibrosis JO: Lancet Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=24836205 #FOAvip Background: Ataluren was developed to restore functional protein production in genetic disorders caused by nonsense mutations, which are the cause of cystic fibrosis (CF) in 10% of patients.. Methods: This randomized, double-blind, placebo-controlled study enrolled 238 patients ?6 years with nmCF to receive oral ataluren 10 mg/kg in the morning, 10 mg/kg mid-day, and 20 mg/kg in the evening or matching placebo for 48 weeks. The primary endpoint was relative change in % predicted forced expiratory volume in one second (FEV1) at Week 48; the secondary endpoint was the rate of pulmonary exacerbations. This study is registered with ClinicalTrials.gov, number NCT00803205. Findings: There was no statistically significant difference in relative change from baseline in % predicted FEV1between ataluren and placebo at Week 48(-2?5% vs -5?5%, p=0.1235). The rate of pulmonary exacerbations was not statistically different between treatment arms (rate ratio 0.77 (95% CI 0.57, 1.05), p=0.0992). However, post hoc analysis of the subgroup of patients not using chronic inhaled tobramycin showed a 5.7% difference in relative change from baseline in % predicted FEV1 between ataluren and placebo at Week 48 (-0.7% vs -6.4%, nominal p=0?008, adjusted for multiplicity p = 0?024) and 40% fewer exacerbations in ataluren-treated patients (OR 0.60 (95% CI 0?42, 0?86), nominal p=0?006, adjusted for multiplicity p = 0?018). Interpretation: While there was no statistically significant improvement in lung function or exacerbation rate in the ITT population of cystic fibrosis patients with nonsense mutations treated with ataluren, treatment might be beneficial for nmCF patients not receiving chronic inhaled tobramycin. Twit Text FOAVip A randomized placebo-controlled trial of ataluren for the treatment of nonsense mutation cystic fibrosis ????Lancet Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=24836205 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24836205 #FOAvip English Wikipedia <ref>{{Cite pmid|24836205}}</ref> A randomized placebo-controlled trial of ataluren for the treatment of nonsense mutation cystic fibrosis #MMPMID24836205 EitanKerem; Konstan MW; De Boeck K; Accurso FJ; Sermet-Gaudelus I; Wilschanski M; Elborn JS; Melotti P; Bronsveld I; Fajac I; Malfroot A; Rosenbluth DB; Walker PA; McColley SA; Knoop C; Quattrucci S; Rietschel E; Zeitlin PL; Barth J; Elfring GL; Welch EM; Branstrom A; Spiegel RJ; Peltz SW; Ajayi T; Rowe SM Lancet Respir Med 2014[Jul]; 2 (7): 539-47 PMID24836205show ga Background: Ataluren was developed to restore functional protein production in genetic disorders caused by nonsense mutations, which are the cause of cystic fibrosis (CF) in 10% of patients.. Methods: This randomized, double-blind, placebo-controlled study enrolled 238 patients ?6 years with nmCF to receive oral ataluren 10 mg/kg in the morning, 10 mg/kg mid-day, and 20 mg/kg in the evening or matching placebo for 48 weeks. The primary endpoint was relative change in % predicted forced expiratory volume in one second (FEV1) at Week 48; the secondary endpoint was the rate of pulmonary exacerbations. This study is registered with ClinicalTrials.gov, number NCT00803205. Findings: There was no statistically significant difference in relative change from baseline in % predicted FEV1between ataluren and placebo at Week 48(-2?5% vs -5?5%, p=0.1235). The rate of pulmonary exacerbations was not statistically different between treatment arms (rate ratio 0.77 (95% CI 0.57, 1.05), p=0.0992). However, post hoc analysis of the subgroup of patients not using chronic inhaled tobramycin showed a 5.7% difference in relative change from baseline in % predicted FEV1 between ataluren and placebo at Week 48 (-0.7% vs -6.4%, nominal p=0?008, adjusted for multiplicity p = 0?024) and 40% fewer exacerbations in ataluren-treated patients (OR 0.60 (95% CI 0?42, 0?86), nominal p=0?006, adjusted for multiplicity p = 0?018). Interpretation: While there was no statistically significant improvement in lung function or exacerbation rate in the ITT population of cystic fibrosis patients with nonsense mutations treated with ataluren, treatment might be beneficial for nmCF patients not receiving chronic inhaled tobramycin. äA randomized placebo-controlled trial of ataluren for the treatment of(epmc).pdf DeepDyve Pubget Overpricing